Alligator Bioscience AB (publ) Interim report January-March 2019
First patient dosed in Phase I clinical study of ATOR-1015Significant events January-March• First patient dosed in Phase I clinical study of ATOR-1015.• New preclinical data presented demonstrating strong anti-tumor effects for the 4-1BB antibody ATOR-1017.• Alligator Bioscience launched RUBY™, a novel concept in bispecific antibody formats. Events after the end of the period• Tumor-localizing properties of ATOR-1015 demonstrated by live imaging.• New preclinical data for ATOR-1144 demonstrates potential for activation of both the innate and the adaptive immune system as well